Top

Journal of Cancer Survivorship

Published in:

01-12-2008

Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls

Authors: Jaime L. Palmer, Theresa Trotter, Anil A. Joy, Linda E. Carlson

Published in: Journal of Cancer Survivorship | Issue 4/2008

Abstract

Introduction

The selective estrogen receptor modulator, Tamoxifen (TAM), is one of the most frequently prescribed drugs for the treatment of breast cancer; however, its effects on the cognition of users have not been adequately studied. Although TAM is an effective anti-estrogen that blocks tumour growth in the breast, it could also influence the activity of other target estrogen sites, including the brain. The exact nature of this interaction is unknown.

Methods

A cross-sectional design was used to compare cognitive task performance of two treatment groups: 1) women using TAM for the treatment of early breast cancer (n = 23); and 2) age-matched, healthy women not using TAM (n = 23). All participants were pre-menopausal, and recipients of chemotherapy were excluded from the study.

Results

It was found that TAM users scored significantly worse than controls on tasks of immediate and delayed visual memory, verbal fluency, immediate verbal memory, visuo-spatial ability, and processing speed.

Discussions/Conclusions

Although limited by the lack of baseline data and pre-morbid intelligence measures, the results of this exploratory study suggest that at least in pre-menopausal women, TAM may exert a widespread negative influence on cognitive abilities.

Implications for Cancer Survivors

Larger, randomized, prospective trials are required to confirm these results; however, TAM use in pre-menopausal breast cancer may be associated with cognitive difficulties. Knowledge and understanding of these complications will be important for professionals in communicating both the benefits and risks of TAM use in breast cancer survivors.

Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of Tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 1995;13:513–29.PubMed

Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609–18. doi:10.1056/NEJM199811263392207.PubMedCrossRef

Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485–93. doi:10.1200/JCO.20.2.485.PubMedCrossRef

Castellon SA, Ganz PA, Bower JE, Peterson L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004;26:955–69. doi:10.1080/13803390490510905.PubMedCrossRef

Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncol 2006;15:422–30. doi:10.1002/pon.964.CrossRef

van Dam FSAM, Schagen SB, Muller MJ, Boogerd W, van der Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high dose versus standard dose chemotherapy. J Natl Cancer Inst 1998;90:210–8. doi:10.1093/jnci/90.3.210.PubMedCrossRef

McEwen B, Alves SE. Estrogen action in the CNS. Endocr Rev 1999;20:279–307. doi:10.1210/er.20.3.279.PubMedCrossRef

Woolley C. Effects of estrogen in the CNS. Curr Opin Neurobiol 1999;9:349–54. doi:10.1016/S0959-4388(99)80051-8.PubMedCrossRef

Wooley C, McEwen B. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 1992;12:2549–54.

10.

Berman KF, Schmidt PJ, Rubinow DR, Danaceau MA, VanHorn JD, Esposito G, et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci USA 1997;94:8836–41. doi:10.1073/pnas.94.16.8836.PubMedCrossRef

11.

Birge SJ, McEwen BS, Wise PM. Effects of estrogen deficiency on brain function. Postgrad Med. 2001, S11–S15, (March).

12.

Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 2004;21:364–71. doi:10.1016/j.neuroimage.2003.08.037.PubMedCrossRef

13.

Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 1998;54:105–12.PubMed

14.

Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 1990;14:26–43. doi:10.1016/0278-2626(90)90058-V.PubMedCrossRef

15.

Kimura D. Estrogen replacement therapy may protect against intellectual decline in post-menopausal women. Horm Behav 1995;29:312–21. doi:10.1006/hbeh.1995.1022.PubMedCrossRef

16.

Phillips SM, Sherwin B. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:497–506. doi:10.1016/0306-4530(92)90008-U.PubMedCrossRef

17.

Sherwin B, Tulandi T. “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with Leiomyomata Uteri. J Clin Endocrin Metab 1996;81:2545–49. doi:10.1210/jc.81.7.2545.CrossRef

18.

Duff SJ, Hampson E. A beneficial effect of estrogen on working memory in post-menopausal women taking hormone replacement therapy. Horm Behav 2000;38:262–76. doi:10.1006/hbeh.2000.1625.PubMedCrossRef

19.

Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen’s effect on cognition. Psychoneuroendocrinology 2001;26:577–90. doi:10.1016/S0306-4530(01)00013-0.PubMedCrossRef

20.

Grigorova M, Sherwin BB, Tulandi T. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology 2006;31:935–47. doi:10.1016/j.psyneuen.2006.05.004.PubMedCrossRef

21.

Silverman I, Phillips K. Effects of estrogen changes during the menstrual cycle on spatial performance. Ethol Sociobiol 1993;14:257–70. doi:10.1016/0162-3095(93)90021-9.CrossRef

22.

Brezden CB, Phillips K, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695–701.PubMed

23.

Paraska KK, Bender CM. Cognitive dysfunction following adjuvant chemotherapy for breast cancer: two case studies. Oncol Nurs Forum 2003;30:473–78. doi:10.1188/03.ONF.473-478.PubMedCrossRef

24.

Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with, breast carcinoma. Cancer 2004;100:2292–9. doi:10.1002/cncr.20272.PubMedCrossRef

25.

Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000;64:165–76. doi:10.1023/A:1006426132338.PubMedCrossRef

26.

Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem 2003;86:405–12. doi:10.1016/j.jsbmb.2003.07.001.CrossRef

27.

McNair DM, Lorr M, Droppleman LF. Profile of mood states. San Diego, California: EdITS/Educational and Industrial Testing Service; 1992.

28.

Meyers J, Meyers K. The Meyers scoring system for the Rey complex figure and recognition trial: professional manual. Odessa, FA: Psychological Assessment Resources; 1995.

29.

Wechsler D. Wechsler memory scale. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.

30.

Vandenberg SG, Kuse AR. Mental rotations: a group test of three-dimensional spatial visualization. Percept Mot Skills 1978;47:599–604.PubMed

31.

Wechsler D. Wechsler adult intelligence scale-III. New York, NY: The Psychological Corporation; 1991.

32.

Spreen O, Strauss E. A compendium of neuropsychological tests. 2nd ed. New York, NY: Oxford University; 1998. p. 263–7. 447–464.

33.

Kimura D. Sex and cognition. Cambridge, MA: MIT; 1999.

34.

Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res 2001;50:86–94. doi:10.1097/00006199-200103000-00004.PubMedCrossRef

35.

Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 2006;54:925–31. doi:10.1111/j.1532-5415.2006.00732.x.PubMedCrossRef

36.

Wefel JS, Lenzi R, Theriault R, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast cancer. Cancer 2004;100:2292-9. doi:10.1002/cncr.20272.PubMedCrossRef

37.

Yeudall LT, Fromm D, Reddon JR, Stefanyk WO. Normative data stratified by age and sex for 12 neuropsychological tests. J Clin Psychol 1986;42:918–46. doi:10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2-Y.CrossRef

38.

Lafayette Instrument Company. Instructions and normative data for model 32020 Purdue Pegboard. Lafayette, IN: Lafayette Instrument Company; 1985.

39.

Eals M, Silverman I. The hunter-gatherer theory of spatial sex differences: proximate factors mediating the female advantage in recall of object arrays. Ethol Sociobiol 1994;15:95–105. doi:10.1016/0162-3095(94)90020-5.CrossRef

40.

Silverman I, Eals M. Sex differences in spatial abilities: evolutionary theory and data. In: Barkow J, Cosmides L, Tooby J, editors. The adapted mind: evolutionary psychology and the generation of culture. New York, NY: Oxford University Press; 1992. p. 487–503.

41.

Kaplan EF, Goodglass H, Weintraub S. The Boston naming test. 2nd ed. Austin, TX: Pro-Ed; 2001.

Title: Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls
Authors: Jaime L. Palmer
Theresa Trotter
Anil A. Joy
Linda E. Carlson
Publication date: 01-12-2008
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 4/2008
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-008-0070-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Discussions/Conclusions

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 4/2008

Distress persists in long-term brain tumor survivors with glioblastoma multiforme

Factors influencing long-term follow-up clinic attendance among survivors of childhood cancer

Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors

Dimensions of physical activity and their relationship to physical and emotional symptoms in breast cancer survivors

Work engagement among breast cancer survivors and the referents: The importance of optimism and social resources at work

Breast self-examination in long-term breast cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer